Related Experiment Video
Updated: Jul 12, 2025

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
Exploiting signaling rewiring in cancer cells with co-existing oncogenic drivers
Roberto Chiarle1,2, Chiara Ambrogio2
1Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
Abstract:
The development of tailored therapies designed to specifically target driver oncogenes has initiated a revolutionary era in cancer biology. The availability of a growing number of selective inhibitors has generated novel experimental and clinical paradigms. These represent an opportunity and a challenge for researchers and clinicians to delve deeper into the intricate dynamics of cancer development and response to treatment. By directly inhibiting key driver oncogenes involved in tumor initiation and progression, scientists have an unprecedented opportunity to conduct longitudinal and clonal evolutionary studies of how cancer cells adapt, rewire, and exploit conflictive or overlapping signaling dependencies in response to treatment in vitro and in vivo. This challenge has to be progressively resolved to discover more effective and personalized cancer therapies.
Insights
Targeted cancer therapies inhibiting driver oncogenes offer new ways to study tumor evolution. Understanding how cancer adapts to these treatments is key to developing more effective, personalized cancer medicines.
Area of Science:
- Oncology
- Cancer Biology
- Molecular Biology
Background:
- Targeted therapies focusing on specific driver oncogenes are revolutionizing cancer treatment.
- Selective inhibitors provide new experimental and clinical approaches to cancer research.
Purpose of the Study:
- To explore the dynamics of cancer development and treatment response using targeted therapies.
- To investigate how cancer cells adapt and evolve under selective pressure from inhibitors.
Main Methods:
- Utilizing selective inhibitors to target key driver oncogenes in vitro and in vivo.
- Conducting longitudinal and clonal evolutionary studies to track cancer cell adaptation.
Main Results:
- Direct inhibition of driver oncogenes allows for detailed observation of cancer cell adaptation.
- Cancer cells exhibit rewiring and exploitation of signaling dependencies in response to treatment.
Conclusions:
- Targeted therapies present a unique opportunity to study cancer evolution in real-time.
- Resolving the challenges of treatment adaptation is crucial for advancing personalized cancer therapies.
Related Concept Videos
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Abnormal Proliferation
Non-Canonical Wnt Signaling Pathways
Canonical Wnt Signaling Pathway

